All In Biotech

Drug Trial Radar · NCT07728396

A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

72

Actual

Start

Jan 28, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years

Conditions

  • COVID - 19

Interventions

  • GC4006ABiological

    administered as a single dose via Intramuscular injection.

  • Normal SalineDrug

    Matching placebo administered as a single dose via Intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Solicited local and systemic AEsTime frame: From baseline up to 7 days
  2. Acute adverse eventsTime frame: From baseline up to 30 minutes
  3. Unsolicited adverse AEsTime frame: From baseline up to 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.